论文部分内容阅读
目的评价基因工程重组ＴＧＦ－α－ＰＥ４０融合蛋白在体外、体内对人脑胶质瘤的治疗作用。方法体外使用改良ＭＴＴ法测定ＴＧＦ－α－ＰＥ４０融合蛋白对体外培养的恶性胶质瘤细胞生长抑制作用，同时检测各细胞株表皮生长因子受体（ＥＧＦＲ）的表达情况；体内利用Ｕ２５１裸鼠移植瘤模型观察不同剂量的融合蛋白对移植瘤体积增长的影响。结果 ＴＧＦ－α－ＰＥ４０融合蛋白对体外培养恶性胶质瘤细胞有明显的生长抑制作用，其作用依赖于肿瘤细胞ＥＧＦＲ的表达；对裸鼠移植瘤，２５０ｕｇ／ｋｇ组用药后２１日内瘤体积无明显增长，抑瘤率为４６．４％。结论ＴＧＦ－α－ＰＥ４０融合蛋白可以选择性地抑制表达ＥＧＦＲ的胶质瘤的生长。
Objective To evaluate the therapeutic effect of genetically engineered recombinant TGF-α-PE40 fusion protein on human glioma in vitro and in vivo. Methods The growth inhibitory effect of TGF-α-PE40 fusion protein on malignant glioma cells in vitro was detected by modified MTT method in vitro. The expression of epidermal growth factor receptor (EGFR) in each cell line was detected at the same time. U251 nude mice Tumor model to observe the different doses of fusion protein on the volume of tumor growth. Results TGF-α-PE40 fusion protein had obvious growth inhibitory effect on malignant glioma cells in vitro. The effect of TGF-α-PE40 fusion protein was dependent on the expression of EGFR in tumor cells. In nude mice, the tumor volume in 250ug / kg group Significant growth, inhibition rate was 46.4%. Conclusion TGF-α-PE40 fusion protein can selectively inhibit the growth of EGFR-expressing glioma.